Balyasny Asset Management
BBNX

Balyasny Asset Management’s Beta Bionics BBNX Stock Holding History

Balyasny Asset Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.19M Buy
617,915
+532,942
+627% +$7.88M 0.01% 1270
2025
Q4 		$2.59M Buy
84,973
+82,458
+3,279% +$2.2M ﹤0.01% 1741
2025
Q3 		$50K Buy
2,515
+2,424
+2,664% +$42.6K ﹤0.01% 2820
2025
Q2 		$1.32K Sell
91
-49,787
-100% -$705K ﹤0.01% 2733
2025
Q1 		$611K Buy
+49,878
New +$930K ﹤0.01% 2201

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's BBNX Position: Q1 2026 in Review

Balyasny Asset Management increased its Beta Bionics (BBNX) stake by 627% in Q1 2026, buying an estimated $7.88M and bringing the position to 617,915 shares worth $6.19M. The position accounts for 0.01% of the portfolio, ranked #1270.

Balyasny Asset Management first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Balyasny Asset Management held 617,915 shares of Beta Bionics worth $6.19M as of Q1 2026.
  • Balyasny Asset Management bought 532,942 Beta Bionics shares in Q1 2026, an estimated $7.88M.
  • Beta Bionics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1270 holding.
  • Balyasny Asset Management first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.